GSK Sells Last Haleon Shares for $1.58 Billion
By Ian Walker
GSK said has sold its remaining stake in Haleon for GBP1.25 billion ($1.58 billion), ending its gradual disposal of shares in the company formed by a joint venture with Pfizer in 2019.
The British pharmaceutical company said Friday that it has sold 385.3 million shares in Haleon at 324 pence each as flagged late Thursday. The shares were sold via an accelerated bookbuild and the price is a 2.5% discount to Haleon's closing price of 332.40 pence on Thursday.
GSK has drawn down its stake in Haleon since last May, while U.S. pharmaceutical giant Pfizer reduced its holdings to 22.6% from 32% in March. Haleon was formed in July 2019 from the merger of GSK and Pfizer's consumer-healthcare businesses before being spun off and listed on the London Stock Exchange in July 2022.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
May 17, 2024 02:24 ET (06:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth